CD2BP2

Summary

CD2BP2 (CD2 cytoplasmic tail binding protein 2, HGNC:1656) is a protein-coding gene on chromosome 16p11.2, encoding CD2 antigen cytoplasmic tail-binding protein 2 (O95400). Involved in pre-mRNA splicing as component of the U5 snRNP complex that is involved in spliceosome assembly. It is a selective cancer dependency (DepMap: 35.1% of cell lines).

This gene encodes a bi-functional protein. In the cytoplasm, the encoded protein binds the cytoplasmic tail of human surface antigen CD2 via its C-terminal GYF domain, and regulate CD2-triggered T lymphocyte activation. In the nucleus, this protein is a component of the U5 small nuclear ribonucleoprotein complex and is involved in RNA splicing. A pseudogene has been identified on chromosome 7. Alternative splicing results in multiple transcript variants but their biological validity has not been determined.

Source: NCBI Gene 10421 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 70 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 35.1% of screened cell lines
• MANE Select transcript: NM_006110

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1656
Approved symbol	CD2BP2
Name	CD2 cytoplasmic tail binding protein 2
Location	16p11.2
Locus type	gene with protein product
Status	Approved
Aliases	LIN1, Snu40, PPP1R59, U5-52K
Ensembl gene	ENSG00000169217
Ensembl biotype	protein_coding
OMIM	604470
Entrez	10421

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 8 protein_coding, 1 retained_intron

ENST00000305596, ENST00000564525, ENST00000569466, ENST00000855800, ENST00000855801, ENST00000855802, ENST00000921035, ENST00000921036, ENST00000943282

RefSeq mRNA: 2 — MANE Select: NM_006110 NM_001243646, NM_006110

CCDS: CCDS10675

Canonical transcript exons

ENST00000305596 — 7 exons

Exon	Start	End
ENSE00001139794	30353181	30353287
ENSE00001139799	30353368	30353800
ENSE00001139805	30353901	30354058
ENSE00001139812	30354184	30354322
ENSE00001316361	30350773	30353095
ENSE00001389090	30355212	30355308
ENSE00003500884	30354604	30354707

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 95.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.1167 / max 146.3959, expressed in 1819 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
157037	27.4075	1818
157038	1.7091	992

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	95.11	gold quality
granulocyte	CL:0000094	95.06	gold quality
left adrenal gland	UBERON:0001234	94.06	gold quality
left adrenal gland cortex	UBERON:0035825	94.04	gold quality
adrenal cortex	UBERON:0001235	93.80	gold quality
right adrenal gland	UBERON:0001233	93.79	gold quality
right adrenal gland cortex	UBERON:0035827	93.69	gold quality
islet of Langerhans	UBERON:0000006	93.45	gold quality
type B pancreatic cell	CL:0000169	93.23	silver quality
left uterine tube	UBERON:0001303	93.23	gold quality
mucosa of stomach	UBERON:0001199	93.15	gold quality
monocyte	CL:0000576	93.05	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.05	gold quality
adrenal gland	UBERON:0002369	93.04	gold quality
mucosa of transverse colon	UBERON:0004991	92.93	gold quality
leukocyte	CL:0000738	92.76	gold quality
mononuclear cell	CL:0000842	92.73	gold quality
right lobe of thyroid gland	UBERON:0001119	92.72	gold quality
left lobe of thyroid gland	UBERON:0001120	92.58	gold quality
popliteal artery	UBERON:0002250	92.55	gold quality
tibial artery	UBERON:0007610	92.55	gold quality
body of stomach	UBERON:0001161	92.49	gold quality
body of pancreas	UBERON:0001150	92.48	gold quality
ganglionic eminence	UBERON:0004023	92.43	gold quality
adenohypophysis	UBERON:0002196	92.37	gold quality
nipple	UBERON:0002030	92.29	gold quality
descending thoracic aorta	UBERON:0002345	92.27	gold quality
aorta	UBERON:0000947	92.26	gold quality
pancreas	UBERON:0001264	92.26	gold quality
lower esophagus muscularis layer	UBERON:0035833	92.14	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.76
E-MTAB-4850	no	271.01

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting CD2BP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-6715B-5P	99.64	69.63	1420
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-4269	99.55	69.89	1373
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-582-5P	99.47	70.79	2635
HSA-MIR-5695	99.41	67.48	1047
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-3125	99.14	68.49	2269
HSA-MIR-6809-5P	99.13	68.45	1223
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-3154	98.94	66.55	1455
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-7851-3P	98.72	64.88	980
HSA-MIR-1227-5P	98.65	65.32	1549
HSA-MIR-210-5P	98.57	64.37	832
HSA-MIR-3136-5P	98.53	67.68	793

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 35.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• CD2BP2 is the ligand of the membrane-proximal proline-rich tandem repeat of CD2 in detergent-soluble membrane compartments. (PMID:12426371)
• there is a function of the GYF domain of CD2BP2 in mediating protein-protein interactions within the spliceosome (PMID:15105431)
• interaction of CD2BP2 with a tri-snRNP bridging protein (Prp6), coupled with CD2BP2’s absence from the tri-snRNP, suggests it might function in tri-snRNP assembly (PMID:15840814)
• findings indicate that CD2BP2 is not a constitutive binding partner or key regulator of CD2-mediated signaling events (PMID:17906334)
• Knockdown of CD2BP2 results in reduced miRNA levels. CD2BP2 stabilizes miRISC and mature miRNAs, maintaining them at levels necessary to properly regulate target gene expression. (PMID:28180320)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cd2bp2	ENSDARG00000027357
mus_musculus	Cd2bp2	ENSMUSG00000042502
rattus_norvegicus	Cd2bp2	ENSRNOG00000017201
drosophila_melanogaster	holn1	FBGN0032250
caenorhabditis_elegans		WBGENE00006563

Protein

Protein identifiers

CD2 antigen cytoplasmic tail-binding protein 2 — O95400 (reviewed: O95400)

Alternative names: U5 snRNP 52K protein

All UniProt accessions (2): O95400, A0A024QZC1

UniProt curated annotations — full annotation on UniProt →

Function. Involved in pre-mRNA splicing as component of the U5 snRNP complex that is involved in spliceosome assembly.

Subunit / interactions. Component of the U5 snRNP complex composed of the U5 snRNA and at least PRPF6, PRPF8, SNRNP200, EFTUD2, SNRNP40, DDX23, TXNL4A and CD2BP2. Interacts directly with TXNL4A and PRPF6. Interacts (via GYF domain) with CD2 (via Pro-rich sequence in the cytoplasmic domain). Interacts with PQBP1.

Subcellular location. Cytoplasm. Nucleus.

RefSeq proteins (2): NP_001230575, NP_006101* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003169	GYF	Domain
IPR035445	GYF-like_dom_sf	Homologous_superfamily
IPR039905	CD2BP2/Lin1	Family

Pfam: PF02213

UniProt features (34 total): helix 11, strand 7, modified residue 6, region of interest 3, sequence variant 2, chain 1, domain 1, cross-link 1, turn 1, compositionally biased region 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
1SYX	X-RAY DIFFRACTION	2.35
4BWS	X-RAY DIFFRACTION	2.5
8Q91	ELECTRON MICROSCOPY	3.1
8Q7Q	ELECTRON MICROSCOPY	3.2
8RC0	ELECTRON MICROSCOPY	3.2
8Q7V	ELECTRON MICROSCOPY	3.8
8Q7W	ELECTRON MICROSCOPY	3.9
8Q7X	ELECTRON MICROSCOPY	4.6
1GYF	SOLUTION NMR
1L2Z	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95400-F1	70.04	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 194, 195, 26, 44, 46, 49, 118

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9918481	Dengue Virus-Host Interactions

MSigDB gene sets: 150 (showing top): SCIBETTA_KDM5B_TARGETS_UP, GGGTGGRR_PAX4_03, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A5, GOBP_SPLICEOSOMAL_TRI_SNRNP_COMPLEX_ASSEMBLY, BLALOCK_ALZHEIMERS_DISEASE_UP, chr16p11, WU_ALZHEIMER_DISEASE_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, MODULE_99, GOBP_PROTEIN_RNA_COMPLEX_ORGANIZATION, GOBP_RNA_SPLICING, HFH1_01, GUO_HEX_TARGETS_UP, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, NRF2_01

GO Biological Process (3): spliceosomal tri-snRNP complex assembly (GO:0000244), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (2): ribonucleoprotein complex binding (GO:0043021), protein binding (GO:0005515)

GO Cellular Component (7): fibrillar center (GO:0001650), nucleus (GO:0005634), nucleoplasm (GO:0005654), U5 snRNP (GO:0005682), cytoplasm (GO:0005737), cytosol (GO:0005829), nuclear speck (GO:0016607)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Dengue Virus Infection	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
RNA processing	2
spliceosomal snRNP assembly	1
mRNA metabolic process	1
protein-containing complex binding	1
binding	1
nucleolus	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
spliceosomal snRNP complex	1
intracellular anatomical structure	1
cytoplasm	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

1430 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD2BP2	CD2	P06729	958
CD2BP2	DDX23	Q9BUQ8	891
CD2BP2	CASK	O14936	720
CD2BP2	EFTUD2	Q15029	713
CD2BP2	AAR2	Q9Y312	689
CD2BP2	CD58	P19256	662
CD2BP2	TXNL4A	P83876	657
CD2BP2	SNRPB	P14678	615
CD2BP2	PRPF6	O94906	613
CD2BP2	IL3RA	P26951	606
CD2BP2	NCAM1	P13591	528
CD2BP2	ITGAX	P20702	524
CD2BP2	FCGR3B	O75015	512
CD2BP2	FCGR3A	P08637	510
CD2BP2	CD19	P15391	506

IntAct

221 interactions, top by confidence:

A	B	Type	Score
CD2BP2	CD2	psi-mi:“MI:0407”(direct interaction)	0.930
PRPF6	CD2BP2	psi-mi:“MI:0915”(physical association)	0.930
PRPF6	CD2BP2	psi-mi:“MI:0407”(direct interaction)	0.930
CD2	CD2BP2	psi-mi:“MI:0407”(direct interaction)	0.930
SNRPF	GEMIN2	psi-mi:“MI:0914”(association)	0.910
SNRPB	CD2BP2	psi-mi:“MI:0915”(physical association)	0.880
CD2BP2	SNRPB	psi-mi:“MI:0915”(physical association)	0.880
SNRPB	CD2BP2	psi-mi:“MI:0403”(colocalization)	0.880
SNRPB	CD2BP2	psi-mi:“MI:0407”(direct interaction)	0.880
CD2BP2	SNRPB	psi-mi:“MI:0915”(physical association)	0.860
SNRPB	CD2BP2	psi-mi:“MI:0915”(physical association)	0.860
CD2BP2	SNRPB	psi-mi:“MI:0407”(direct interaction)	0.860
SNRPB	CD2BP2	psi-mi:“MI:0407”(direct interaction)	0.860
CD2BP2	ACAD11	psi-mi:“MI:0915”(physical association)	0.800
CD2BP2	SNRNP200	psi-mi:“MI:0914”(association)	0.800
TXNL4A	CD2BP2	psi-mi:“MI:0915”(physical association)	0.790
TXNL4A	CD2BP2	psi-mi:“MI:0407”(direct interaction)	0.790
PRPF6	SNRNP200	psi-mi:“MI:0914”(association)	0.770
SNRPE	GEMIN2	psi-mi:“MI:0914”(association)	0.770
SART1	PRPF3	psi-mi:“MI:0914”(association)	0.720
SNRPD2	GEMIN2	psi-mi:“MI:0914”(association)	0.710
SNRPG	GEMIN2	psi-mi:“MI:0914”(association)	0.710

BioGRID (415): CD2BP2 (Two-hybrid), CD2BP2 (Two-hybrid), CD2BP2 (Affinity Capture-RNA), CD2BP2 (Affinity Capture-RNA), CD2BP2 (Affinity Capture-MS), CD2BP2 (Affinity Capture-MS), CD2BP2 (Affinity Capture-MS), CD2BP2 (Co-fractionation), CD2BP2 (Co-fractionation), CD2BP2 (Co-fractionation), CD2BP2 (Co-fractionation), CD2BP2 (Co-fractionation), CD2BP2 (Co-fractionation), DDX23 (Co-fractionation), POLR3C (Co-fractionation)

ESM2 similar proteins: A1L131, A4IFK7, C5IJB0, D3ZND0, F1MX48, O60232, O95400, P35689, Q0VCT3, Q17QX2, Q2KIJ6, Q2YD98, Q3ZBK7, Q3ZBN4, Q4R4I0, Q53GS7, Q5EAN7, Q5FVK6, Q5PPF5, Q5RAS2, Q5T0F9, Q68F60, Q69ZT1, Q6AYI4, Q6NU18, Q6TLH3, Q7L4P6, Q7TMX5, Q8BL74, Q8BRN9, Q8BSI6, Q8C0R7, Q8C6D4, Q8N5A5, Q8R322, Q8VDM1, Q91VL8, Q91WA6, Q91WR3, Q969X0

Diamond homologs: O95400, Q9CWK3, Q9VKV5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 150 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metabolism of non-coding RNA	6	34.6×	7e-07
mRNA Splicing - Minor Pathway	14	28.5×	2e-15
mRNA Splicing - Major Pathway	39	19.4×	7e-38
mRNA Splicing	19	19.0×	2e-17
mRNA Polyadenylation	21	16.8×	4e-18
SARS-CoV-2 modulates host translation machinery	8	16.3×	1e-06
Processing of Capped Intron-Containing Pre-mRNA	20	14.9×	2e-16
RNA Polymerase II Transcription Termination	7	14.0×	3e-05

GO biological processes:

GO term	Partners	Fold	FDR
RNA splicing, via transesterification reactions	10	48.0×	8e-13
spliceosomal complex assembly	10	46.3×	1e-12
spliceosomal snRNP assembly	10	44.7×	1e-12
U2-type prespliceosome assembly	8	38.4×	2e-09
mRNA splicing, via spliceosome	33	23.2×	2e-33
RNA splicing	25	17.0×	3e-21
regulation of alternative mRNA splicing, via spliceosome	7	13.2×	9e-05
mRNA processing	21	12.7×	4e-15

Disease & clinical

Clinical variants and AI predictions

ClinVar

70 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	58
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

907 predictions. Top by Δscore:

Variant	Effect	Δscore
16:30353712:TGGGC:T	donor_gain	1.0000
16:30353721:A:AC	donor_gain	1.0000
16:30353797:TCACC:T	acceptor_loss	1.0000
16:30353799:ACCT:A	acceptor_loss	1.0000
16:30353802:T:A	acceptor_loss	1.0000
16:30354181:TACC:T	donor_loss	1.0000
16:30354183:C:A	donor_loss	1.0000
16:30354183:CCTT:C	donor_gain	1.0000
16:30354319:CCAG:C	acceptor_gain	1.0000
16:30354320:CAGC:C	acceptor_gain	1.0000
16:30354323:C:A	acceptor_loss	1.0000
16:30354323:C:CC	acceptor_gain	1.0000
16:30354337:C:CT	acceptor_gain	1.0000
16:30354337:C:T	acceptor_gain	1.0000
16:30354338:A:T	acceptor_gain	1.0000
16:30354598:CCTCA:C	donor_loss	1.0000
16:30354599:CTCAC:C	donor_loss	1.0000
16:30354600:TCACC:T	donor_loss	1.0000
16:30354601:CACC:C	donor_loss	1.0000
16:30354602:A:AG	donor_loss	1.0000
16:30354603:C:CA	donor_loss	1.0000
16:30354603:CCTT:C	donor_gain	1.0000
16:30354704:CAAG:C	acceptor_gain	1.0000
16:30354705:AAG:A	acceptor_gain	1.0000
16:30354708:C:CC	acceptor_gain	1.0000
16:30355208:TCAC:T	donor_loss	1.0000
16:30355209:CACC:C	donor_loss	1.0000
16:30355210:ACCT:A	donor_loss	1.0000
16:30353288:C:CC	acceptor_gain	0.9900
16:30353722:T:C	donor_gain	0.9900

AlphaMissense

2224 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:30354006:A:C	F90L	1.000
16:30354006:A:T	F90L	1.000
16:30354008:A:G	F90L	1.000
16:30353247:C:A	W283C	0.999
16:30353247:C:G	W283C	0.999
16:30353919:C:A	W119C	0.999
16:30353919:C:G	W119C	0.999
16:30353921:A:G	W119R	0.999
16:30353921:A:T	W119R	0.999
16:30353973:A:C	F101L	0.999
16:30353973:A:T	F101L	0.999
16:30353974:A:G	F101S	0.999
16:30353975:A:G	F101L	0.999
16:30353185:A:G	M304T	0.998
16:30353249:A:G	W283R	0.998
16:30353249:A:T	W283R	0.998
16:30353974:A:C	F101C	0.998
16:30353981:C:G	G99R	0.998
16:30354001:A:G	L92P	0.998
16:30354007:A:C	F90C	0.998
16:30354008:A:T	F90I	0.998
16:30353052:C:G	R320P	0.997
16:30353957:A:C	Y107D	0.997
16:30353962:C:A	G105V	0.997
16:30354007:A:G	F90S	0.997
16:30353000:A:C	F337L	0.996
16:30353000:A:T	F337L	0.996
16:30353002:A:G	F337L	0.996
16:30353054:G:C	C319W	0.996
16:30353917:A:G	L120P	0.996

dbSNP variants (sampled 300 via entrez): RS1000267867 (16:30352463 A>G,T), RS1000671819 (16:30356398 T>C), RS1000848578 (16:30351491 A>C), RS1001652822 (16:30353151 C>G,T), RS1001890416 (16:30356707 C>A,G), RS1001951451 (16:30355017 G>C,T), RS1002090171 (16:30357050 C>T), RS1002252597 (16:30351992 T>C), RS1002300626 (16:30355141 C>T), RS1002477481 (16:30351818 G>A), RS1003090135 (16:30351229 C>T), RS1003133563 (16:30354218 G>C), RS1003362180 (16:30355897 T>A,C), RS1003897151 (16:30354583 A>G), RS1004096786 (16:30354747 G>A,C)

Disease associations

OMIM: gene MIM:604470 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010703_269	Brain morphology (MOSTest)	4.000000e-13

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066341 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	3
ochratoxin A	decreases expression	2
Air Pollutants	affects expression, increases abundance, decreases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
Particulate Matter	decreases expression, increases abundance, affects expression, increases reaction	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	increases activity, affects binding, decreases expression	1
bisphenol A	affects cotreatment, increases expression	1
sodium arsenate	decreases expression	1
sodium arsenite	increases expression	1
beta-methylcholine	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine	affects expression, increases reaction	1
abrine	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
Leflunomide	decreases expression	1
Arbutin	decreases expression	1
Atrazine	decreases expression	1
Vehicle Emissions	affects expression, increases reaction	1
Cadmium	increases expression, increases abundance	1
Caffeine	increases phosphorylation	1
Dexamethasone	affects cotreatment, increases expression	1
Diazinon	increases methylation	1
Enzyme Inhibitors	increases O-linked glycosylation, decreases activity	1
Indomethacin	increases expression, affects cotreatment	1
Ivermectin	decreases expression	1
Lead	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651069	Binding	Binding affinity to human CD2BP2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

4 cell lines: 3 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1D9	Abcam HCT 116 CD2BP2 KO	Cancer cell line	Male
CVCL_B2TT	Abcam HEK293T CD2BP2 KO	Transformed cell line	Female
CVCL_SH69	HAP1 CD2BP2 (-) 1	Cancer cell line	Male
CVCL_SH70	HAP1 CD2BP2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.